Bio Techne Corp TECH
We take great care to ensure that the data presented and summarized in this overview for BIO-TECHNE Corp is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TECH
View all-
Vanguard Group Inc Valley Forge, PA18.4MShares$1.01 Billion0.02% of portfolio
-
Black Rock Inc. New York, NY15MShares$819 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD8.85MShares$483 Million0.05% of portfolio
-
Morgan Stanley New York, NY6.58MShares$359 Million0.02% of portfolio
-
State Street Corp Boston, MA5.86MShares$320 Million0.01% of portfolio
-
Geode Capital Management, LLC Boston, MA4.06MShares$222 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.66MShares$200 Million0.03% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN3.44MShares$188 Million0.05% of portfolio
-
Select Equity Group, L.P. New York, NY2.92MShares$159 Million0.74% of portfolio
-
Bamco Inc New York, NY2.8MShares$153 Million0.41% of portfolio
Latest Institutional Activity in TECH
Top Purchases
Top Sells
About TECH
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen brands. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at TECH
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Aug 25
2025
|
Roeland Nusse Director |
SELL
Open market or private sale
|
Direct |
17,040
-27.66%
|
$954,240
$56.36 P/Share
|
Aug 25
2025
|
Roeland Nusse Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,040
+21.67%
|
$357,840
$21.84 P/Share
|
Aug 25
2025
|
Robert V Baumgartner Director |
SELL
Open market or private sale
|
Direct |
17,040
-27.53%
|
$954,240
$56.21 P/Share
|
Aug 25
2025
|
Robert V Baumgartner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,040
+21.59%
|
$357,840
$21.84 P/Share
|
Aug 15
2025
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,926
-1.46%
|
$102,078
$53.6 P/Share
|
Aug 15
2025
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,010
+2.95%
|
-
|
Aug 15
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-5.05%
|
$42,559
$53.6 P/Share
|
Aug 15
2025
|
William Geist PRESIDENT, PROTEIN SCIENCES |
BUY
Exercise of conversion of derivative security
|
Direct |
2,623
+14.15%
|
-
|
Aug 15
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
SELL
Payment of exercise price or tax liability
|
Direct |
880
-15.67%
|
$46,640
$53.6 P/Share
|
Aug 15
2025
|
Matthew Mc Manus President - Diag & Spatial Bio |
BUY
Exercise of conversion of derivative security
|
Direct |
2,637
+31.96%
|
-
|
Aug 15
2025
|
Shane Bohnen SVP - General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
527
-10.73%
|
$27,931
$53.6 P/Share
|
Aug 15
2025
|
Shane Bohnen SVP - General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
1,718
+25.91%
|
-
|
Aug 15
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,305
-7.79%
|
$228,165
$53.6 P/Share
|
Aug 15
2025
|
Kim Kelderman Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,543
+13.39%
|
-
|
Aug 15
2025
|
Amy E. Herr Director |
SELL
Payment of exercise price or tax liability
|
Indirect |
101
-4.48%
|
$5,353
$53.6 P/Share
|
Aug 15
2025
|
Amy E. Herr Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
279
+11.01%
|
-
|
Aug 07
2025
|
John L Higgins Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,040
+7.17%
|
$105,840
$21.84 P/Share
|
Jul 29
2025
|
James Hippel CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
147,431
-53.57%
|
$8,550,998
$58.55 P/Share
|
Jul 29
2025
|
James Hippel CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
168,620
+37.99%
|
$7,419,280
$44.33 P/Share
|
Jul 22
2025
|
Kim Kelderman Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,649
-48.3%
|
$2,313,397
$53.12 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 12.7K shares |
---|---|
Exercise of conversion of derivative security | 381K shares |
Payment of exercise price or tax liability | 250K shares |
---|---|
Open market or private sale | 50.6K shares |